Targeted therapy in melanoma

Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 364, 2507, 10.1056/NEJMoa1103782 Dhomen, 2009, BRAF signaling and targeted therapies in melanoma, Hematol Oncol Clin North Am, 23, 529, 10.1016/j.hoc.2009.04.001 Long, 2011, Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma, J Clin Oncol, 29, 1239, 10.1200/JCO.2010.32.4327 Pollock, 2003, High frequency of BRAF mutations in nevi, Nat Genet, 33, 19, 10.1038/ng1054 Landi, 2006, MC1R germline variants confer risk for BRAF-mutant melanoma, Science, 313, 521, 10.1126/science.1127515 Viros, 2008, Improving melanoma classification by integrating genetic and morphologic features, PLoS Med, 5, e120, 10.1371/journal.pmed.0050120 Boni, 2010, Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function, Cancer Res, 70, 5213, 10.1158/0008-5472.CAN-10-0118 Kono, 2006, Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression, Mol Cancer Res, 4, 779, 10.1158/1541-7786.MCR-06-0077 Sumimoto, 2006, The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells, J Exp Med, 203, 1651, 10.1084/jem.20051848 Sondak, 2011, Ipilimumab, Nat Rev Drug Disc, 10, 411, 10.1038/nrd3463 Harding, 2012, Vermurafenib sensitivity skin reaction after ipilimumab, N Engl J Med, 366, 866, 10.1056/NEJMc1114329 Wilhelm, 2004, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Res, 64, 7099, 10.1158/0008-5472.CAN-04-1443 Sharma, 2005, Mutant V599E B-Raf regulates growth and vascular development of malignant melanoma tumors, Cancer Res, 65, 2412, 10.1158/0008-5472.CAN-04-2423 Hauschild, 2009, Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma, J Clin Oncol, 27, 2823, 10.1200/JCO.2007.15.7636 Tsai, 2008, Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity, Proc Natl Acad Sci U S A, 105, 3041, 10.1073/pnas.0711741105 Bollag, 2010, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma, Nature, 467, 596, 10.1038/nature09454 Kefford, 2010, Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors, J Clin Oncol, 28, 15, 10.1200/jco.2010.28.15_suppl.8503 Montagut, 2008, Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma, Cancer Res, 68, 4853, 10.1158/0008-5472.CAN-07-6787 Paraiso, 2010, Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy, Br J Cancer, 102, 1724, 10.1038/sj.bjc.6605714 Rubinstein, 2010, Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032, J Transl Med, 8, 67, 10.1186/1479-5876-8-67 Solit, 2006, BRAF mutation predicts sensitivity to MEK inhibition, Nature, 439, 358, 10.1038/nature04304 Haass, 2008, The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel, Clin Cancer Res, 14, 230, 10.1158/1078-0432.CCR-07-1440 Smalley, 2007, Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels, Br J Cancer, 96, 445, 10.1038/sj.bjc.6603596 Smalley, 2006, Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases, Mol Cancer Ther, 5, 1136, 10.1158/1535-7163.MCT-06-0084 Eisen, 2006, Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis, Br J Cancer, 95, 581, 10.1038/sj.bjc.6603291 Jilaveanu, 2009, Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib, Clin Cancer Res, 15, 1076, 10.1158/1078-0432.CCR-08-2280 Handolias, 2010, Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT, Br J Cancer, 102, 1219, 10.1038/sj.bjc.6605635 Flaherty, 2010, Inhibition of mutated, activated BRAF in metastatic melanoma, N Engl J Med, 363, 809, 10.1056/NEJMoa1002011 Smalley, 2012, Meeting report from the 2011 International Melanoma Congress, Tampa, Florida, Pigm Cell Melanoma Res, 25, E1, 10.1111/j.1755-148X.2011.00943.x Sosman, 2012, Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib, N Engl J Med, 366, 707, 10.1056/NEJMoa1112302 Chapman, 2012, Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF V600E-mutated melanoma, J Clin Oncol, 30, 10.1200/jco.2012.30.15_suppl.8502 Hauschild, 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 380, 358, 10.1016/S0140-6736(12)60868-X Infante, 2011, Phase I/II study of the oral MEK1/2 inhibitor GSK1120212 dosed in combination with the oral BRAF inhibitor GSK2118436, J Clin Oncol, 29, CRA8503, 10.1200/jco.2011.29.18_suppl.cra8503 Gilmartin, 2011, GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition, Clin Cancer Res, 17, 989, 10.1158/1078-0432.CCR-10-2200 Kim, 2011, A phase II study of the MEK1/MEK2 inhibitor GSK21120212 in metastatic BRAF V600E or K mutant cutaneous melanoma patients previously treated with or without a BRAF inhibitor, Pigm Cell Melanoma Res, 24 Flaherty, 2012, Improved survival with MEK inhibition in BRAF-mutated melanoma, New Engl J Med, 367, 107, 10.1056/NEJMoa1203421 Xing, 2012, Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E) BRAF, Oncogene, 31, 446, 10.1038/onc.2011.250 Paraiso, 2011, PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression, Cancer Res, 71, 2750, 10.1158/0008-5472.CAN-10-2954 Nathanson, 2011, Tumor genetic analysis of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436, J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.8501 Smalley, 2008, Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas, Mol Cancer Ther, 7, 2876, 10.1158/1535-7163.MCT-08-0431 Chen, 2011, Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling, Cancer Res, 71, 4280, 10.1158/0008-5472.CAN-10-3761 Fedorenko, 2011, Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma, Biochem Pharmacol, 82, 201, 10.1016/j.bcp.2011.05.015 Jiang, 2011, MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720, Clin Cancer Res, 17, 721, 10.1158/1078-0432.CCR-10-2225 Basile, 2012, Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells, Oncogene, 31, 2471, 10.1038/onc.2011.424 Sawyers, 2004, Targeted cancer therapy, Nature, 432, 294, 10.1038/nature03095 Yauch, 2009, Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma, Science, 326, 572, 10.1126/science.1179386 Duensing, 2010, Targeted therapies of gastrointestinal stromal tumors (GIST)—the next frontiers, Biochem Pharmacol, 80, 575, 10.1016/j.bcp.2010.04.006 Whittaker, 2010, Gatekeeper mutations mediate resistance to BRAF-targeted therapies, Sci Trans Med, 9, 35 Nazarian, 2010, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, 468, 973, 10.1038/nature09626 Villanueva, 2010, Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K, Cancer Cell, 18, 683, 10.1016/j.ccr.2010.11.023 Wagle, 2011, Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling, J Clin Oncol, 29, 3085, 10.1200/JCO.2010.33.2312 Poulikakos, 2011, RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E), Nature, 480, 387, 10.1038/nature10662 Shi, 2012, Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired BRAF inhibitor resistance, Nat Commun, 6, 724, 10.1038/ncomms1727 Paraiso, 2012, The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms, Clin Cancer Res, 18, 2502, 10.1158/1078-0432.CCR-11-2612 Flaherty, 2011, Phase I/II expansion cohort of BRAF inhibitor GSK2118436 + MEK inhibitor GSK21120212 in patients with BRAF mutant metastatic melanoma who progressed on a prior BRAF inhibitor, Pigm Cell Melanoma Res, 24 Weber, 2012, Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor darbraenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma, J Clin Oncol, 30, 10.1200/jco.2012.30.15_suppl.8510 Dankort, 2009, Braf(V600E) cooperates with PTEN loss to induce metastatic melanoma, Nat Genet, 41, 544, 10.1038/ng.356 Curtin, 2006, Somatic activation of KIT in distinct subtypes of melanoma, J Clin Oncol, 24, 4340, 10.1200/JCO.2006.06.2984 Woodman, 2009, Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates, Mol Cancer Ther, 8, 2079, 10.1158/1535-7163.MCT-09-0459 Guo, 2011, Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification, J Clin Oncol, 29, 2904, 10.1200/JCO.2010.33.9275 Wyman, 2006, Multi-center phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy, Cancer, 106, 2005, 10.1002/cncr.21834 Ugurel, 2005, Lack of clinical efficacy of imatinib in metastatic melanoma, Br J Cancer, 92, 1398, 10.1038/sj.bjc.6602529 Padua, 1984, A novel transforming gene in a human malignant melanoma cell line, Nature, 311, 671, 10.1038/311671a0 Tsao, 2004, Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma, J Invest Dermatol, 122, 337, 10.1046/j.0022-202X.2004.22243.x Heidorn, 2010, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF, Cell, 140, 209, 10.1016/j.cell.2009.12.040 Poulikakos, 2010, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF, Nature, 464, 427, 10.1038/nature08902 Weber, 2003, Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanoma of the uvea, Lab Invest, 83, 1771, 10.1097/01.LAB.0000101732.89463.29 Van Raamsdonk, 2009, Frequent somatic muations of GNAQ in uveal melanoma and blue naevi, Nature, 457, 599, 10.1038/nature07586 Ambrosini, 2010, The MEK inhibitor AZD244 (selumetinib) is active in GNAQ mutant ocular melanoma cells Adjei, 2008, Phase I pharmacokinetic and pharmacodynamic study of the oral small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer, J Clin Oncol, 26, 2139, 10.1200/JCO.2007.14.4956 Dummer, 2008, AZD2444 (ARRY-142886) vs TMZ in patients with advanced melanoma: an open-labeled randomized, multicenter, phase II study, J Clin Oncol, 20 Guldberg, 1997, Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma, Cancer Res, 57, 3660 Schwartz, 2009, A phase I study of XL281, a selective oral RAF kinase in patients with advanced solid tumors, J Clin Oncol, 27, 10.1200/jco.2009.27.15_suppl.3513 Robert, 2012, Cutaneous toxicites of targeted therapies, Semin Oncol, 39, 227, 10.1053/j.seminoncol.2012.01.009 Kee, 2011, Squamous cell tumors from RAF inhibitor treated patients have a distinct mutational profile supporting a mechanism of therapy induced tumorigenesis in Ras-primed cells, Pigm Cell Melanoma Res, 24 Oberholzer, 2012, RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors, J Clin Oncol, 20, 316, 10.1200/JCO.2011.36.7680 Su, 2012, RAS mutations in cutaneous squamous cell carcinomas in patients treated with BRAF inhibitors, N Engl J Med, 366, 207, 10.1056/NEJMoa1105358 Agero, 2006, Dermatologic side effects associated with the epidermal growth factor receptor inhibitors, J Am Acad Dermatol, 55, 657, 10.1016/j.jaad.2005.10.010 Robert, 2005, Cutaneous side-effects of kinase inhibitors and blocking antibodies, Lancet Oncol, 6, 491, 10.1016/S1470-2045(05)70243-6 Osio, 2009, Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors, Br J Dermatol, 161, 515, 10.1111/j.1365-2133.2009.09214.x Lee, 2009, Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib, Br J Dermatol, 161, 1045, 10.1111/j.1365-2133.2009.09290.x Kong, 2007, Keratoacanthomas associated with sorafenib therapy, J Am Acad Dermatol, 56, 171, 10.1016/j.jaad.2006.10.032 Autier, 2008, Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor, Arch Dermatol, 144, 886, 10.1001/archderm.144.7.886 Lipworth, 2009, Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib, Oncology, 77, 257, 10.1159/000258880 Marquez, 2009, Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene, Cancer Control, 16, 66, 10.1177/107327480901600110 Kong, 2009, Array of cutaneous adverse effects associated with sorafenib, J Am Acad Dermatol, 61, 360, 10.1016/j.jaad.2009.02.004 Zimmer, 2012, Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management, Arch Dermatol, 148, 357, 10.1001/archdermatol.2011.2842 Arora, 2004, Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate, Ann Oncol, 15, 358, 10.1093/annonc/mdh068 Bennani-Lahlou, 2008, Eruptive nevi associated with sorafenib treatment, Ann Dermatol Venereol, 135, 672, 10.1016/j.annder.2008.04.016 John, 2011, Identification of BRAF mutations in eruptive melanocytic envi: new insights into melanomagenesis?, Expert Rev Anticancer Ther, 11, 711, 10.1586/era.11.30